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ABSTRACT
Background
Chondroitin sulfate proteoglycan (CSPG) is a major component of the glial scar. It is
considered to be a major obstacle for central nervous system (CNS) recovery after injury,
especially in light of its well-known activity in limiting axonal growth. Therefore, its degradation
has become a key therapeutic goal in the field of CNS regeneration. Yet, the abundant de novo
synthesis of CSPG in response to CNS injury is puzzling. This apparent dichotomy led us to
hypothesize that CSPG plays a beneficial role in the repair process, which might have been
previously overlooked because of nonoptimal regulation of its levels. This hypothesis is tested
in the present study.
Methods and Findings
We inflicted spinal cord injury in adult mice and examined the effects of CSPG on the
recovery process. We used xyloside to inhibit CSPG formation at different time points after the
injury and analyzed the phenotype acquired by the microglia/macrophages in the lesion site.
To distinguish between the resident microglia and infiltrating monocytes, we used chimeric
mice whose bone marrow-derived myeloid cells expressed GFP. We found that CSPG plays a
key role during the acute recovery stage after spinal cord injury in mice. Inhibition of CSPG
synthesis immediately after injury impaired functional motor recovery and increased tissue loss.
Using the chimeric mice we found that the immediate inhibition of CSPG production caused a
dramatic effect on the spatial organization of the infiltrating myeloid cells around the lesion
site, decreased insulin-like growth factor 1 (IGF-1) production by microglia/macrophages, and
increased tumor necrosis factor alpha (TNF-a) levels. In contrast, delayed inhibition, allowing
CSPG synthesis during the first 2 d following injury, with subsequent inhibition, improved
recovery. Using in vitro studies, we showed that CSPG directly activated microglia/
macrophages via the CD44 receptor and modulated neurotrophic factor secretion by these
cells.
Conclusions
Our results show that CSPG plays a pivotal role in the repair of injured spinal cord and in the
recovery of motor function during the acute phase after the injury; CSPG spatially and
temporally controls activity of infiltrating blood-borne monocytes and resident microglia. The
distinction made in this study between the beneficial role of CSPG during the acute stage and
its deleterious effect at later stages emphasizes the need to retain the endogenous potential of
this molecule in repair by controlling its levels at different stages of post-injury repair.
The Editors’ Summary of this article follows the references.
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The poor recovery of the central nervous system (CNS)
following an injury is generally attributed to the accumu-
lation of compounds that mediate self-perpetuating degen-
eration, the presence of growth inhibitors [1,2], formation of
the glial scar [3,4], and a malfunction of the immune response
mediated mostly by microglia/macrophages [5–8]. The ex-
tracellular matrix molecule chondroitin sulfate proteoglycan
(CSPG) is a major constituent of the glial scar [1,9–11], and it
is intensively secreted following CNS injury. Its effect on
recovery in the CNS has gained a negative reputation that
derives mainly from studies in which it was shown to impede
axonal regeneration [9,10].T h i sp e r c e p t i o np r o m p t e d
attempts to overcome this obstacle to recovery, especially
by the use of chondroitinase ABC (ChABC), a CSPG-
degrading enzyme [1,12,13], aimed at elimination of CSPG
from the injury site. Moreover, the observed spatial and
temporal association between CSPG deposition and the local
immune response was thought to support the negative roles
of both in recovery from CNS injury [3].
Accumulated data suggest, however, that a tightly regulated
and timely immune response is needed for recovery [14–17].
It is now apparent that the phenotype of microglia/macro-
phages is not uniform [15,18–24], and that in response to
different stimuli these cells can acquire either destructive
[25–31] or a beneﬁcial phenotype [32–34]. These latter
observations, together with the fact that the postinjury
increase in CSPG is not restricted to the CNS but is a general
phenomenon associated with the healing of wounds [35], led
us to postulate that the intense de novo synthesis of CSPG
following injury might have a role in the repair process by
regulating the local immune response, and that its overall
negative reputation might reﬂect nonoptimal regulation of
its production and/or degradation.
Methods
Animals
Two mouse strains were used in the experiments, inbred
adult wild-type C57Bl/6J mice (supplied by the Animal
Breeding Center of The Weizmann Institute of Science) and
CX3CR1
GFP/þ mice (a generous gift of Stefan Jung at the
Weizmann Institute). The CX3CR1
GFP/þ mice are heterozy-
gotic mice with green ﬂuorescent protein (GFP) inserted in
the CX3CR1 locus in one allele, while a normal allele enables
the continued expression of CX3CR1 [36]. In these mice, all
myeloid cells express GFP. Chimeric mice were generated as
described below, by replacing the bone marrow of wild-type
mice with bone marrow derived from the CX3CR1
GFP/þ mice.
Newborn C57Bl/6J mice were used for the extraction of
microglia, used in the in vitro studies. All animals were
handled according to the regulations formulated by the
Institutional Animal Care and Use Committee (IACUC).
Summary of Animal Groups
The experiments described in Figure 1 included ﬁve C57Bl/
6J and four chimeric mice subjected to spinal cord injury.
Figure 2 shows data from 13 C57Bl/6J and eight chimeric mice
subjected to spinal cord injury and treated with either PBS or
xyloside, and analyzed by immunohistochemistry. In Figure 3,
for the dose–response to xyloside, 21 animals were subjected
to spinal cord injury and were divided into four experimental
groups. The functional recovery assessments shown in Figure
3 and Figure 4 included 42 mice subjected to spinal cord
injury. These mice were divided into ﬁve groups and were
assessed for motor recovery. At the end point, the mice were
killed and lesion size was determined by immunohistochem-
istry (Figure 4H and 4I). An additional eight mice were used
for biotinylated dextran amine (BDA) analysis (Figure 4F and
4G). CSPG levels were determined in an independent
experiment (Figure 4J and 4K) that included 16 mice,
subjected to spinal cord injury, divided into four groups
and analyzed 14 d later. For Western blotting, nine mice
divided into three groups were included and were analyzed 7
d after the injury. In Figure 5, IGF-1 assessment was examined
14 d after spinal cord injury, by immunohistochemistry and
ELISA, and included 14 and 16 mice, respectively. For the
assessment of GFPþ inﬁltrating cells (Figure 5D), 14 d after
the injury, a total of eight chimeric mice were subjected to
spinal cord injury and divided into two groups. Results in
Figures 6 and 7 do not include in vivo experiments. In Figure
8, 33 mice were subjected to spinal cord injury and divided
into two groups (PBS control and CSPG-DS treatment) and
were followed for motor functional recovery. For histology,
12 mice were also subjected to spinal cord injury and assessed
14 d later by immunohistochemistry. BDA analysis was
performed on another group of eight animals, subjected to
injury and either left untreated or treated with CSPG-DS. For
all ELISA results reported within the text, analysis was
performed 14 d after spinal cord injury, and four mice were
used in each group.
Spinal Cord Injury and Assessment of Functional Recovery
The spinal cords of anesthetized mice were exposed by
laminectomy at T12, and a force of 200 kdyn was placed for 1
s on the cord by using the Inﬁnite Horizon spinal impactor
(Precision Systems, Lexington, Kentucky), a device shown to
inﬂict a well-calibrated injury of the spinal cord. The animals
were maintained on twice daily bladder expression. Func-
tional recovery from spinal cord contusion in mice was
determined by hind limb locomotor performance. Recovery
was scored by the Basso mouse scale (BMS), an open-ﬁeld
locomotor rating scale [37], that was developed speciﬁcally
for mice, with scores ranging from 0 (complete paralysis) to 9
(normal mobility). Blind scoring ensured that observers were
not aware of the treatment received by each group (7–20 mice
per group; mice were excluded in cases of peritoneal
infection, wounds in the hind limbs, and tail and foot
autophagia). Twice a week, locomotor activities of mice in an
open ﬁeld were monitored by placing the mouse for 4 min at
the center of a circular enclosure (90 cm in diameter, 7 cm
wall height) made of molded plastic with a smooth, nonslip
ﬂoor.
ELISA
Wild-type C57Bl/6J mice were killed and their spinal cords
were removed 14 d after spinal cord injury. A section of 1
mm
2 from the lesion area or from a noninjured area 1 cm
distally to the injury site (repeated with six mice per group)
was excised. The excised tissue was homogenized in PBS.
Similarly, in an independent experiment, we excised the
lesion area in PBS or xyloside-treated (0.8 mg/mouse for 6 d,
immediately, 2 or 7 d after the injury) mice (four mice per
group). Two freeze-thaw cycles were performed to break the
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min at 5,000g, the total protein levels were determined by
Bradford reagent, and equal amounts of protein in equal
volumes were then assayed using ELISA (Quantikine Mouse
IGF-1 or TNF-a Immunoassay, R&D Systems), according to
the instructions of the manufacturer. Results are expressed by
picograms of protein per milliliter of homogenate.
Chimeric Mice
C57BL/6J-CX3CR1
GFP/þ chimeric mice were generated by
lethal whole body irradiation (950 rad, with shielding of the
brain) of C57BL/6J mice followed by reconstitution with 4 3
10
6 bone marrow cells isolated from the CX3CR1
GFP/þ mice
(harvested from the femora and tibiae, by ﬂushing the bones
with Dulbecco PBS under aseptic conditions, and then
Figure 1. Microglia and Blood-borne Monocytes Associated with CSPG Found in the Lesion Site Express High Levels of IGF-1
Paraffin-embedded spinal cord sections were prepared from the lesion site 14 d after injury.
(A and B) Sections were immunolabeled for IGF-1 (A) or BDNF (B) (scale bar 500 lm).
(C) Sections were labeled with IB-4 (green), to identify microglia/macrophages and IGF-1 (red; left panels) or BDNF (yellow; right panels) (scale bars, 10
lm; arrows indicate double-labeled cells).
(D) Labeling by CS-56 (blue), a marker of CSPG and IGF-1 (red, upper panels) colocalized at the margins of the lesion site. BDNF expression (yellow, lower
panels) is not specifically colocalized with CS-56 immunoreactivity (blue, all panels; scale bar, 100 lm). High-power images of the boxed area in the left
panels are shown on the right (scale bar, 20 lm).
(E and F) Quantitative analysis of IGF-1 (E) and BDNF (F) immunoreactivity, at the epicenter and the margins of the lesion calibrated to either intensity
per square millimeter. Total intensity in the examined region was normalized to the size of the area (left graphs, arbitrary units, Student t-test, [E] t ¼
 5.03, df ¼ 8; p ¼ 0.001; [F] t ¼ 4.55, df ¼ 8, p ¼ 0.002) or intensity per cell (total intensity in the examined region normalized to the number of IB-4
labeled cells; right graphs, arbitrary units, Student t-test: [E] t¼ 7.4, df¼8, p¼0.0001; [F] t¼0.97, df¼8, p¼0.36). *p , 0.05; **p , 0.01; ***p , 0.001.
(G) Sections from GFP-chimeric mice labeled for GFP (blood-derived macrophages; green) in non-injured and injured mice (scale bar, 100 lm).
(H and I) Lesion site in chimeric injured mice, labeled for CS-56 (blue) (H) and GFP (green) or IB-4 (red) (I) and GFP (green; scale bars 10 lm).
(J) High magnification of cells from the marginal area of the lesion, indicating that both GFP-positive (green) and GFP-negative cells express IGF-1 (red;
scale bar, 20 lm). Arrows indicate blood-derived macrophages (GFP-positive) cells expressing IGF-1. In all panels, boundaries between the epicenter and
the margins are marked by dashed line.
doi:10.1371/journal.pmed.0050171.g001
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rpm at 4 8C), in which GFP is expressed under the promoter
of the chemokine receptor, CX3CR1. In the chimeric mice
formed following bone marrow reconstitution, the bone
marrow-derived cells (blood-borne monocytes) originating
from the CX3CR1
GFP/þ mice express GFP; however, the
resident microglia are GFP-negative. This system thus allows
the resident microglia and the inﬁltrating macrophages to be
distinguished. The mice were grafted with bone marrow cells
2 mo before the spinal cord injury.
Figure 2. CSPG Modulates Microglia/Macrophage Activation and Spatial Localization in the Lesion Site
After spinal cord injury, mice were injected IP with xyloside (1.2 mg/mouse/d, for 6 d), a pharmacological inhibitor of CSPG synthesis.
(A) CS-56 staining of spinal cord sections for the presence of CSPG (scale bar, 250 lm).
(B) Quantitative analysis of CSPG intensity in the diameter of 1 mm around the epicenter (arbitrary units; Student t-test, t ¼ 5.61, df ¼ 9, p ¼ 0.0003).
(C) Staining for IGF-1 (red; scale bar, 250 lm).
(D) Quantitative analysis of IGF-1 immunoreactivity per square millimeter, at the site (arbitrary units; Student t-test, t ¼ 4.5, df ¼ 8, p ¼ 0.002).
(E) Staining for BDNF (yellow; scale bar, 250 lm).
(F) Quantitative analysis of BDNF immunoreactivity at the site (arbitrary units; nonsignificant according to Student t-test, t ¼ 0.21, df ¼ 11, p ¼ 0.83).
(G) Representative photomicrographs of CS-56-labeled spinal cord sections from mice treated with xyloside (scale bar, 250 lm). The boxed area in the
left panel is magnified on the right and shows labeling for IGF-1 (red) and CS-56 (CSPG; white; scale bar, 20 lm).
(H) Scheme showing experimental time scale. Bone marrow chimeras were generated by reconstitution of irradiated C57BL/6J mice with CX3CR1
GFP/þ
bone marrow. After 2 mo, chimeric mice were subjected to spinal cord injury and injected IP with xyloside.
(I) Staining for GFP (green; blood-borne macrophages) and IB-4 (red; microglia/macrophages) at the injury site in control (left) and in xyloside-treated
(right) animals (scale bar, 100 lm; ** p , 0.01; *** p , 0.001).
doi:10.1371/journal.pmed.0050171.g002
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Xyloside (4-methylumbelliferyl-b-D-xylopyranoside; Sigma-
Aldrich) was injected intraperitoneally (IP) every day starting
either immediately after the injury, 2 d later, or 7 d after the
injury. The mice were injected twice daily for 5 d. The mice
were analyzed for functional recovery with the BMS, cytokine
expression by ELISA, and CSPG expression by Western
blotting (using wild-type C57Bl/6J mice) and histology (using
wild-type and chimeric mice). For functional analysis, mice
were examined up to 60 d after injury. For histological
analysis mice were killed 14 d after the injury. Several dosages
of xyloside, adapted from another experimental system [38],
were tested in order to choose the lowest effective dose (0.8
mg/mouse). To exclude the possibility that the effects of
xyloside result from a peripheral effect on the bone marrow
or cell composition in the blood, rather than from the
elimination of CSPG from the lesion site, we examined the
effects of xyloside application on cellular blood composition,
bone marrow cell populations, and bone marrow architecture
(Figure S1). All the examined parameters were similar in the
xyloside-treated and the control groups (three mice per
group). Analysis was performed using standard procedures by
a commercial service (Pathovet, Kefar Bilu, Israel).
CSPG-DS Administration
CSPG-DS (6-sulfated disaccharides; Sigma-Aldrich), were
administered to mice by repeated intravenous injections (5 lg
dissolved in PBS) on days 1, 4, 7, 10, and 13 after injury.
Anterograde BDA Labeling
Wild-type C57Bl/6J mice that were followed for functional
recovery were anesthetized 60 d after the injury, and injected
bilaterally using a stereotaxic frame, with the high-resolution
anterograde tracer BDA (10,000 MW lysine-ﬁxable biotin
dextran amine; Molecular Probes, Eugene, OR; 1.2 ll of 10%
wt/vol BDA solution in 0.01 M PB). BDA was injected into
both motor cortices. A 30-gauge Hamilton needle was
lowered through the cortex (1 mm) and four injections of
0.3 ll per site were administered within a perimeter deﬁned
coronally by bregma 1.7 mm to  0.7 mm, and sagittally 0.5–
1.5 mm from the sagittal suture, bilaterally. Injections were
performed over 3–5 min and the needle was slowly removed.
The mice were killed and perfused 14 d after BDA injection.
For histological assessment of the BDA tracing, spinal cords,
and brains were dissected, and sections (30 lm) of the
thoracic spinal cord comprising the lesion site were cut either
horizontally (ﬂoating) or longitudinally, and stained for BDA
by the use of either nickel-enhanced diaminobenzidine
protocol [39], or ﬂuorescently labeled Cy3-strepavidin (Jack-
son ImmunoResearch), as indicated in the relevant legends.
Injection site and labeling are shown in Figure S2. To
quantify anterogradely labeled ﬁbers caudal to the lesion, we
calculated the labeling caudal to the lesion site relative to the
amount of BDA-labeled axons rostal to the lesion for each
animal.
Immunohistochemistry
Mice subjected to spinal cord injury were killed 14 d later,
their spinal cords were prepared for histology and analyzed as
described before [40] (3–5 mice per group). The following
antibodies were used: mouse anti-CS-56 (1:100; Sigma-Aldrich),
chicken anti-BDNF (1:100; Promega), goat anti-IGF-1 (1:20;
R&D Systems) rabbit anti-mouse glial ﬁbrillary acid protein
(GFAP 1:200; DakoCytomation), and rabbit anti-GFP (1:100;
MBL). For microglial cell/macrophage labeling we used FITC-
conjugated Bandeiraea simplicifolia isolectin B4 (IB-4; 1:50;
Sigma-Aldrich) for 1 h in the secondary antibody solution.
Secondary antibodies used were Cy3-conjugated donkey anti-
goat antibody, Cy3-conjugated donkey anti-chicken antibody,
and Cy2/Cy5 conjugated donkey anti-mouse antibody (1:200; all
from Jackson ImmunoResearch). The slides were exposed to
Hoechst stain (1:2000; Invitrogen Probes) for 1 min. The same
antibodies were used for immunohistochemical analysis of the
microglia cultured in vitro.
Myelin integrity was qualitatively examined on parafﬁn-
embedded sections that were stained with Luxol fast blue for
Figure 3. CSPG Plays a Key Role in Recovery from Spinal Cord Injury
(A) Staining for myelin by Luxol (blue) and to nuclei by Nissel (pink) (scale bar, 500 lm).
(B) Quantitative analysis of the size of the site of injury as a function of the xyloside dosages, determined by Luxol and Nissel staining (ANOVA, F[3,17]¼
37.5, p ¼ 0.0001, followed by Fisher test for differences between groups). Results were significant at the 5% level in all cases except for xyloside
treatment (0.3 mg/d) compared to PBS, and for xyloside treatment at 0.3 mg/d compared to 0.6 mg/d.
(C) Immunohistochemistry of xyloside-treated spinal cords, using anti-GFAP (green) antibodies and IB-4 labeling (red) (scale bar, 250 lm).
(D) Mean locomotor score (BMS) of individual mice on day 36 after spinal cord injury with and without xyloside treatment (immediately after injury 0.8
mg/mouse/d; Student t-test, t ¼ 2.67, df ¼ 14, p ¼ 0.018). * p , 0.05.
doi:10.1371/journal.pmed.0050171.g003
PLoS Medicine | www.plosmedicine.org August 2008 | Volume 5 | Issue 8 | e171 1266
Chondroitin in Spinal Cord Repairmyelin and Nissel for the nuclei and the thin cytoplasmic
layer around them. With the aid of Image-Pro (Media
Cybernetics) the results were analyzed by determination of
the density or by measurement of the lesion area by an
observer who was blinded to the treatment received by the
mice. For tissue cultured cell phosphorylated ERK labeling,
mouse anti phosphoERK (Santa Cruz) was used. For analysis,
500–1,000 cells were sampled for each marker.
Quantification
For microscopic analysis a Nikon ﬂorescent microscope
was used (Nikon E800). Intensity of staining was calibrated
using Image-Pro Plus software by an observer blind to the
identity of the slides. To calibrate intensity of labeling, an
average of sampled background areas was subtracted from
the total intensity counted. To demonstrate intensity per
square millimeter, the total intensity in the examined region
Figure 4. Restricting CSPG Secretion to the Acute Stage after Injury Improves Functional Recovery
(A) Schematic representation of the experimental time scale. Mice were subjected to contusive spinal cord injury and were treated with xyloside (0.8
mg/mouse/d for 6 d) at different time points after the injury. Locomotion was recorded, and is given by the mean locomotor scores (BMS) for each
group.
(B) Xyloside application started 2 d after the injury (repeated measures ANOVA, F[1,15] ¼ 7.426 [between groups], p ¼ 0.016).
(C) Xyloside application started immediately after the injury (two factor repeated measures ANOVA, F[1,14] ¼ 15.481 [between groups], p ¼ 0.0015).
(D) Xyloside application started 7 d after the injury (repeated measures ANOVA, F[1,15] ¼ 0.093 [between groups], p ¼ 0.764).
(E) Fold change in functional recovery on day 30 after the injury between each treatment compared to their matched untreated control (ANOVA, F[2,27]
¼ 16.64, p ¼ 0.0001).
(F) BDA tracing of the corticospinal tract, caudal to the lesion site in a xyloside-treated mouse; photomicrographs show cornal sections excised from
mice treated with xyloside on day 0 (left) or 2 (right) after the injury (scale bars, 250 lm). Insert shows the site from which the images were taken.
(G) Quantitative analysis of BDA labeling. To quantify labeled fibers caudal to the lesion, we calculated the labeling caudal to the lesion site relative to
the amount of BDA rostal to the lesion for each animal (mean 6 SD; Student t-test, t ¼  3.99, df ¼ 6, p ¼ 0.007).
(H) Immunohistochemistry of xyloside-treated spinal cords, using anti-GFAP (green) antibodies and IB-4 labeling (red; scale bars, 250 lm).
(I) Quantitative analysis of the size of the injury site as a function of the treatment, determined by Luxol and Nissel staining (ANOVA, F[3,26]¼43.03, p¼
0.0001).
(J) CS-56 staining of spinal cord sections, excised from mice 14 d after the injury, for the presence of CSPG (scale bar, 250 lm). The dashed line
demarcates the lesion site, defined based on GFAP labeling.
(K) Quantification of CSPG intensity (ANOVA, F[3,12] ¼ 7.619, p ¼ 0.0041).
(L) Western blot analysis of CSPG levels in the control group (PBS) and in the groups receiving xyloside treatment on day 0 or day 2 after the injury
(excised 7 d after the injury). b-actin was used as a control for protein levels. Fold decrease in CSPG levels, relative to PBS control, are shown (n¼3 mice
per group).
ANOVA in (I) and (K) followed by the Fisher test for differences among groups (significant at the 5% level). Asterisks (G, I, and K) denote statistically
significant differences between the indicated groups, or compared to the relevant control: *p , 0.05; **p , 0.01.
doi:10.1371/journal.pmed.0050171.g004
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numbers, we counted the cells using manual tagging within
the Image-Pro Plus software. To determine intensity per cell,
total intensity in the examined region was normalized to the
number of cells. For each assessment, four or ﬁve animals per
group were examined, sections from three different depths
were examined, and at least 1,000 cells per group were
included. The margins and the lesion size were deﬁned by the
area demarcated by GFAP immunolabeling or Luxol/Nissel
staining (the lesion was identiﬁed as the area that was not
labeled for myelin by Luxol) and quantiﬁed by Image-Pro
Plus software.
Western Blotting
Wild-type C57Bl/6J mice were killed 7 d after the spinal
cord injury, and sections of the spinal cord (5 mm around the
lesion site) were removed. The sections were shock-frozen in
liquid nitrogen and homogenized in 150 mM NaCl, 1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris (pH
8.0) containing proteinase inhibitor cocktail (Sigma), 1 mM
leupeptin, and 1 mM pepstatin. The homogenates were
incubated for 1 h and centrifuged at 10,000g for 15 min.
Bradford analysis was performed to determine protein
concentrations, and similar levels of protein were subjected
to 5% SDS-PAGE and detected using CS-56 antibody (Sigma)
and anti-b-actin. The gels were calibrated using the NIH
Image program, the intensity of each CS-56 band was
calibrated relative to its b-actin levels, and the fold decrease
compared to PBS treatment was determined (three mice were
examined in each group).
Tissue Culture
To prepare cultures of microglia, a distinct group of
neonatal (P0–P1) C57Bl/6J mice was used. The mice were
killed and their brains were stripped of their meninges and
minced with scissors under a dissecting microscope (Zeiss,
Stemi DV4, Germany) in Leibovitz-15 medium (Biological
Industries, Beit Ha-Emek, Israel). After trypsinization (0.5%
trypsin, 10 min, in 5% CO2 at 37 8C), the tissue was triturated.
The cell suspension was washed in culture medium (DMEM
supplemented with 10% fetal calf serum [Sigma-Aldrich], 1
mM l-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin,
and 100 lg/ml streptomycin). The mixed brain glial cells were
cultured in 5% CO2 at 37 8C in 75-cm
2 Falcon tissue culture
ﬂasks (BD Biosciences) that had been coated with poly-d-
lysine (PDL) (10 lg/ml; Sigma-Aldrich) in borate buffer (15.45
g boric acid [Merck] dissolved in 500 ml of sterile water [pH
8]) for 1 h, then rinsed thoroughly with sterile, glass-distilled
water. The medium was changed after 24 h in culture, and
every second day thereafter, for a total culture time of 10–14
d. Microglia were shaken off the primary mixed brain glial
cell cultures (150 rpm, 6 h, 37 8C) with maximum yields
between day 10 and 14, and seeded (10
5 cells/ml) on coverslips
coated with PDL or CSPG (Sigma-Aldrich) for the indicated
time periods. Cells were grown in culture medium for
microglia (RPMI-1640 medium [Sigma-Aldrich] supple-
mented with 10% fetal calf serum, 1 mM l-glutamine, 1 mM
sodium pyruvate, 50 lM b-mercaptoethanol, 100 U/ml
penicillin, and 100 lg/ml streptomycin). Since CSPG was
used in the present study as a matrix component rather than
as a soluble compound, its effect was monitored as a function
of time, rather than as a function of dose. Cell proliferation
was visualized by staining with 5-bromo-deoxyuridine (BrdU,
2.5 lM; Sigma-Aldrich). Lipopolysaccharide (LPS; Sigma-
Aldrich) was added to the culture medium after the cells
were cultured on CSPG or treated with CSPG-DS. For
neutralization assays, anti-mouse CD44 (BD Pharmingen)
neutralizing antibody was used. CSPG-DS was added to PDL-
cultured microglia at the indicated concentrations.
Assay of Nitric Oxide
Nitric oxide release was assayed according to the method of
Griess [41].
RNA Purification, cDNA Synthesis, and Reverse
Transcription PCR Analysis
These procedures were performed as previously described
[18]. The following primers were used: tumor necrosis factor
alpha (TNF-a), 59-GGGACAGTGACCTGGACTGT-39,5 9-
Figure 5. Delayed Inhibition of CSPG Synthesis Positively Modulates
Activation and Spatial Localization of Microglia/Macrophages in the
Lesion Site
Spinal cords were excised (14 d after the lesion) from animals that were
subjected to spinal cord injury and treated with either PBS or with
xyloside administered on day 2 or day 7 following the insult.
(A) Quantitative analysis of IGF-1 immunoreactivity per square millimeter
at the site (ANOVA, F[2,11] ¼ 22.78, p ¼ 0.0001).
(B) Quantitative analysis of IGF-1 protein concentration determined by
ELISA of spinal cord tissue (ANOVA, F[3,12] ¼ 32.138, p ¼ 0.0001).
(C) Experimental time scale. CX3CR1
GFP/þ . wild type bone marrow
chimeras were generated by reconstitution of irradiated C57BL/6J mice
with CX3CR1
GFP/þ bone marrow. Chimeric mice were subjected to spinal
cord injury and injected IP with xyloside starting from day 2 after the
injury.
(D) Staining for GFP (green; blood-borne macrophages) and IB-4 (red;
microglia/macrophages) at the injury site in control (PBS) and in delayed
(day 2) xyloside-treatment group (scale bar, 250 lm).
ANOVA followed by the Fisher test for differences between groups;
significant differences at the 5% level are denoted by asterisks. All the
groups in (B) were significantly different from uninjured control.
doi:10.1371/journal.pmed.0050171.g005
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(A) IB-4 labeling (green) and Hoechst (nuclear; blue) of microglia cultured on PDL or on CSPG for 48 h showing morphological changes in the CSPG-
cultured microglia (scale bar, 10 lm).
(B) BrdU incorporation showing increased proliferation induced by microglia cultured on CSPG relative to PDL-cultured microglia (scale bar, 100 lm).
(C) Quantitative analysis of the proportion of BrdU-incorporating cells in the total population of IB-4þ cells (Student t-test, t ¼ 4.24, df ¼ 6, p ¼ 0.005).
(D) Semi-quantitative PCR analyses of IGF-1 and BDNF expression by microglia cultured for 12 h on PDL or on CSPG. Values represent relative amounts
of amplified mRNA normalized against b-actin in the same sample, and are represented as fold induction relative to control microglia cultured on PDL.
(E) IGF-1 (red) and BDNF (green) expression in microglia cultured for 18 h on PDL or on CSPG (scale bar, 20 lm). Hoechst labeling is blue.
(F) Quantitative analysis of IGF-1 immunoreactivity in microglia cultured for 12, 18, and 48 h on CSPG (ANOVA, F[2,6]¼185.2, p¼0.0001, followed by the
Fisher test).
(G) Semi-quantitative PCR analyses of IRS-1 expression by microglia cultured on PDL and on CSPG.
(H) Semi-quantitative PCR analyses of MMP-2 and MMP-9 mRNA in microglia cultured on PDL and on CSPG for various time periods. Values represent
relative amounts of amplified mRNA normalized against b-actin in the same sample, and are represented as fold change in microglia cultured on CSPG
relative to PDL at the same time point (C, CSPG; P, PDL).
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1 (IGF-1), 59-TGGATGCTCTTCAGTTCGTG-39,5 9-GTCTTG-
GGCATGTCAGTGTG-39; insulin receptor substrate 1 (IRS-1),
59-AGCGAGCTCGAGCATGGCGAGCCCTC-39,5 9-ATCG-
TCGACTCGAGATCTCCGAGTCA-39; brain-derived neuro-
trophic factor (BDNF), 59-GCTGACACTTTTGAGCAC-39,5 9-
AAATCCACTATCTTCCCC-39; matrix metalloproteinase 2
(MMP-2), 59-CTTCGCTCGTTTCCTTCAAC-39,5 9-AGAG-
TGAGGAGGGGAACCAT-39;M M P - 9 ,5 9-TGAATCAGCTG-
GCTTTTGTG-39, 5’GTGGATAGCTCGGTGGTGTT-39; and
b-actin, 59-TAAAACGCAGCTCAGTAACAGTCCG-39,5 9-
TGGAATCCTGTGGCATCCATGAAAC-39.
Statistical Analysis
Data were analyzed using the Student t-test to compare
between two groups; two-way ANOVA followed by the Fisher
LSD (least signiﬁcant difference) procedure to compare
between multiple numbers of groups and repeated ANOVA
was used in the functional BMS scoring. The speciﬁc tests
used to analyze each set of experiments are indicated in the
legends.
Results
CSPG Present in the Lesion Site after Spinal Cord Injury
Modulates Neurotrophic Factor Expression by Microglia/
Macrophages
After CNS injury, microglia/macrophages become activated
and accumulate at the lesion site. We ﬁrst examined neuro-
trophic factor expression by these cells. We inﬂicted a well-
calibrated contusive injury at the thoracic segments of the
mice spinal cords (T-12), which resulted in paralysis of the
hind limbs. To delineate the lesion site in spinal cord
sections, we used GFAP labeling. We found that microglia/
macrophages located at the lesion site expressed high levels of
IGF-1 in addition to BDNF (Figure 1A and 1B, respectively).
Quantitation of IGF-1 levels in tissue homogenates using
ELISA revealed a 3-fold increase in a homogenate of tissue
excised from the site of injury, relative to a homogenate of
tissue excised from a region far from the injured site (mean 6
SD: 175 6 13.5 pg/ml in the lesion area compared to 55 6 5.8
pg/ml in the distal area; n¼4). Immunohistochemical analysis
revealed that IGF-1 was expressed mostly by the microglia/
macrophages found at the margins of the lesion as opposed to
BDNF, which was not speciﬁcally elevated in these cells
(Figure 1C–1F).
The observed localized expression of IGF-1 encouraged us
to examine its association with CSPG, shown to be expressed
mainly at the margins of the lesion. Immunohistochemical
analysis showed that microglia/macrophages that were spa-
tially associated with CSPG expressed IGF-1 in abundance
(Figure 1D and 1E). In contrast, BDNF expression was not
related to the presence of CSPG (Figure 1D and 1F).
The increased expression of IGF-1 by the microglia/
macrophages that were spatially associated with CSPG could
reﬂect a direct interaction of these cells with CSPG.
Alternatively, it could be an outcome of additional differ-
ences between the margins and the epicenter of the lesion,
such as the origin of the microglia/macrophages; a prefer-
ential presence of either microglia or blood-borne monocytes
[42] at the margins of the lesion. To address this issue, we used
chimeric mice whose bone marrow cells had been replaced in
adulthood with green ﬂuorescent protein (GFP)-expressing
bone marrow cells (isolated from transgenic mice that express
GFP in their myeloid cells [36]). First we determined the basal
number of blood-borne monocytes (identiﬁed by their GFP
expression) in naı ¨ve spinal cords of the chimeric mice. We did
not detect any inﬁltrating blood-borne monocytes in the
naı ¨ve cords (Figure 1G). A recent report identiﬁed approx-
imately 3 6 1 inﬁltrating cells per square millimeter, in a
noninjured spinal cord under similar conditions [43].
Following injury, numerous inﬁltrating blood-borne mono-
cytes (314 6 185 cells/mm
2) were found at the margins of the
lesion but almost none at the epicenter of the lesion (Figure
1G and 1H); nevertheless, a small number of GFP
þ (green)
cells were also noted in the epicenter. Resident microglia,
however, were distributed both in the margins and at the
epicenter of the injured site (Figure 1I). Analysis of IGF-1
expression revealed that in the CSPG-rich areas both micro-
glia and blood-borne monocytes expressed increased levels of
IGF-1 (Figure 1J). These results strengthened our observation
(I) Nitric oxide levels in the culture media of microglia cultured for 48 h on PDL or CSPG or in the presence of LPS (50 ng/ml) (ANOVA, F[2,9]¼114.9, p¼
0.0001, followed by the Fisher test).
(J) Semi-quantitative PCR analysis of TNF-a expression indicating that TNF-a was not increased in CSPG-activated microglia, but was significantly
increased upon activation of microglia by LPS (12 h). Values represent relative amounts of amplified mRNA normalized against b-actin in the same
sample, and are represented as fold induction relative to control microglia cultured on PDL.
(K–M) Cells were cultured on PDL and CSPG, 24 h prior to their stimulation with LPS for an additional 24 h. Quantitative analysis of TNF-a production (K)
or cell-body size (L) in microglia activated by increasing doses of LPS (M), representative photos; TNF-a (red) and IB-4 (green) labeling of microglia (scale
bar, 20 lm). Two-way ANOVA was used for statistical analysis in (K) (F[7,17]¼34.3, p¼0.0001) and (L) (F[7,53]¼19.47, p¼0.0001), followed by the Fisher
test (*p ¼ 0.05). The changes were significant between the CSPG- and PDL-cultured microglia. All data are from one of at least three independent
experiments with replicate cultures. *p , 0.05; **p , 0.01.
doi:10.1371/journal.pmed.0050171.g006
Figure 7. Microglial Activation by CSPG Is Mediated by CD44
(A) Anti-phospho-ERK1/2 labeling (green) indicating increased phosphor-
ylation of ERK1/2 in microglia (IB-4; red) cultured on CSPG. In this culture,
addition of CD44-neutralizing antibodies to the medium resulted in
decreased ERK1/2 phosphorylation (scale bar, 20 lm). Arrows indicate
microglia labeled with pERK1/2.
(B) Quantitative analysis of pERK1/2-positive, IB-4-positive cells. Data are
from one of at least three independent experiments in replicate cultures
(P, PDL; C, CSPG; ANOVA, F[3,17] ¼ 158.7, p ¼ 0.0001; followed by Fisher
test, *p ¼ 0.05).
doi:10.1371/journal.pmed.0050171.g007
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(A) Mean locomotor score (BMS) for each group during the 60-d recovery period (repeated measures ANOVA, F[1,31] ¼ 15.47 [between groups], p ¼
0.0004). After injuries of similar severity, recovery was significantly improved as a result of CSPG-DS treatment.
(B–D) BMS scores of individual mice on day 60 after spinal cord injury (Student t-test, t¼ 5.52, df¼31, p¼0.0001) (B). Spinal cord sections from injured
mice treated with CSPG-DS (5 lg) or PBS were immunolabeled with CS-56 (CSPG, red; scale bar 100 lm) (C), GFAP (astrocytes, green), and IB-4
(microglia/macrophages, red; scale bar, 100 lm) of the lesion site in coronal sections (D).
(E) Quantitative analysis of the IB-4-labeled area, indicative of the lesion site (Student t-test, t ¼  5.53, df ¼ 10, p ¼ 0.0003).
(F) Quantitative analysis of BDA labeling. Sections that contained more than two labeled fibers caudal to the lesion site were counted and presented in
percentage (Student t-test, t ¼  4.81, df ¼ 6, p ¼ 0.003).
(G) IGF-1 immunoreactivity (red) in microglia treated with CSPG-DS in the presence or absence of LPS (scale bar, 20 lm).
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cells and their spatial association with the margin of the
lesion.
CSPG Modulates Microglia/Macrophage Activation and
Spatial Localization in the Lesion Site
To examine whether CSPG directly affects the microglia
and the blood-borne monocytes found in its proximity, we
used xyloside, a pharmacological inhibitor of CSPG biosyn-
thesis. Xyloside inhibits the biosynthesis of CSPG, and has
been previously used to study the role of CSPG in axonal
growth both in vivo and in vitro [38,44]. We treated mice with
xyloside immediately after injury. Using anti-CSPG antibody
(CS-56), we veriﬁed that this treatment resulted in a decrease
in CSPG accumulation (Figure 2A and 2B). We found that
xyloside treatment signiﬁcantly attenuated IGF-1 expression
(Figure 2C and 2D). The reduction in IGF-1 expression was
quantitatively veriﬁed by ELISA, using homogenate of tissues
excised from the site of injury of PBS- and xyloside-treated
mice (151 6 23 pg/ml in the lesion area of PBS-treated
compared to 93 6 22 pg/ml in the xyloside-treated mice;
mean 6 SD obtained from eight animals, analyzed separately;
p , 0.001; Student t-test). In line with the reported inverse
relationship between IGF-1 and TNF-a levels [18,45], the
xyloside treatment also caused an increase in TNF- levels (11
6 1.29 pg/ml in the PBS-treated group compared to 16.9 6
3.1 pg/ml in the xyloside treatment; p ¼ 0.004 Student t-test)
determined by ELISA. On the other hand, xyloside treatment
had no effect on BDNF levels (Figure 2E and 2F). In the few
areas within the margins where xyloside failed to fully inhibit
CSPG formation, we detected IGF-1–expressing cells (Figure
2G). Xyloside treatment of spinally injured chimeric mice
(with GFP-expressing blood-borne monocytes; Figure 2H)
revealed that the disruption of CSPG deposition resulted in
an inﬁltration of blood-borne macrophages into the epi-
center of the lesion, an area where they were not found in the
presence of CSPG (Figure 2I). The possibility that the changes
in the inﬁltration of macrophages might reﬂect a change in
blood or bone marrow composition caused by the xyloside
treatment was excluded by the demonstration that the bone
marrow architecture and cellular composition as well as the
cell populations in the blood were not affected by xyloside
treatment (Figure S1). Thus, our data indicate that the
increased IGF-1 expression by microglia and blood-borne
monocytes, and the spatial organization of these cells at the
lesion site, are related to the presence of CSPG.
CSPG Plays a Key Role in Recovery from Spinal Cord Injury
To address the relevance of CSPG production to the
recovery from injury, we ﬁrst assessed the size of the lesion
site by immunohistochemical analysis. Staining for myelin
with Luxol fast blue, and for cell nuclei with Nissel, revealed a
dose-dependent increase in the size of the lesion site in
correlation with the increase in the xyloside dosages (Figure
3A and 3B). Labeling of astrocytes with GFAP and of
microglia/macrophages with IB-4 yielded similar results with
respect to the lesion size (Figure 3C), indicating that in the
absence of CSPG, tissue damage is markedly increased.
To further evaluate the relevance of CSPG production to
functional recovery, we performed an additional experiment
applying xyloside immediately after injury, and assessed the
functional recovery using the Basso Mouse Scale, BMS. This
scale evaluates locomotion in an open ﬁeld, where a score of 0
indicates complete paralysis and a score of 9 indicates normal
function. Treatment with xyloside immediately after injury
signiﬁcantly reduced the spontaneous recovery, resulting in
lower motor function of the hind limbs (Figure 3D). This
result emphasizes that CSPG plays a beneﬁcial role in the
spontaneous recovery from spinal cord injury.
Distinct Effects of CSPG in the Acute and Subacute Phases
after Spinal Cord Injury
The observed beneﬁcial role of CSPG and the well-
documented inhibitory effect of CSPG on axonal growth
[1,9,10] raise an apparent discrepancy. We postulated that
this discrepancy reﬂects a nonoptimal postinjury regulation
of CSPG levels and timing. Thus, for example, although CSPG
is needed to induce the neuroprotective phenotype of
microglia/macrophages in the acute phase (from immediately
after injury to 1 or 2 d later), its continuing production in the
subsequent (subacute) phase might be overwhelming and thus
inhibits axonal growth. To examine the possibility that timing
is crucial factor in the presence of CSPG, we again employed
the experimental paradigm of spinal cord injury, but this
time applied xyloside at the subacute phase (2 d after injury)
so that CSPG biosynthesis was restricted to the acute phase.
As a control, we treated an additional group of spinally
injured mice with xyloside on day 7 after injury, when CSPG
levels are no longer increased, and therefore was not
expected to be affected by xyloside treatment (Figure 4A).
Application of xyloside 2 d after the insult (in the subacute
phase) promoted motor functional recovery (Figure 4B and
4E), in contrast to its application immediately after the injury,
when it was detrimental to recovery (Figure 4C and 4E).
Application of xyloside at day 7 did not affect recovery
(Figure 4D and 4E). Next, we examined whether these
functional effects were also reﬂected by the extent of
anterograde-labeled descending ﬁbers, caudally to the lesion
site, following the immediate (day 0) and delayed (day 2)
treatment with xyloside. We subjected the mice to ante-
rograde labeling by injecting the tracer BDA into their motor
cortex. A higher percentage of BDA-labeled ﬁbers could be
seen caudally to the lesion site in the group that was treated
with xyloside on day 2 after the injury compared to the group
that was treated with xyloside immediately after injury
(Figures 4F, 4G, and S2). Consistent with the functional and
(H) Quantitative analysis of IGF-1 immunoreactivity in the CSPG-DS-treated microglia, with (gray) and without LPS (black) (ANOVA, F[5,19]¼10.63, p¼
0.0001; followed by the Fisher test; the changes were significant at 95% between the CSPG-DS-treated microglia and the PBS-treated controls).
(I) BDNF immnoreactivity (green) and Hoechst labeling (blue) in microglia treated with CSPG-DS (scale bar, 10 lm).
(J) Quantitative analysis of BDNF immunoreactivity in the CSPG-DS-treated microglia (ANOVA, F[2,9] ¼ 23.16, p ¼ 0.0003; followed by the Fisher test).
(K) BDNF labeling (yellow) of microglia in the lesion site (scale bar, 20 lm). The image depicts the marginal area of the lesion.
(L) IGF-1 staining (red) of microglia in the lesion (scale 20 lm). The image depicts the epicenter of the lesion. The dashed line demarcates the lesion site.
All data in (G)–(J) are from one of at least three independent experiments with replicate cultures.
*p , 0.05; **p , 0.01; ***p , 0.001.
doi:10.1371/journal.pmed.0050171.g008
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Chondroitin in Spinal Cord Repairmorphological observations described above, the lesion site
in the animals that received immediate xyloside treatment
(day 0) was enlarged, while treatment delayed to day 2
resulted in a reduction in the size of the damaged site (Figure
4H and 4I) as detected by GFAP/IB-4 immunohistochemistry;
treatment on day 7 had no functional or morphological
effect. The different effects of xyloside treatment in the
various regimes (day 0, 2, 7) further support the contention
that the effect of xyloside is local on CSPG synthesis, rather
than an unrelated systemic effect. Examining CSPG levels in
the different treatment groups indicated that both in the
immediate treatment (day 0) and in the delayed treatment
(day 2), there was a decrease in the overall levels of CSPG
detected by immunohistochemistry (Figure 4J and 4K) and by
Western blotting (Figure 4L).
Based on these ﬁndings, we wished to examine whether the
delayed (day 2) xyloside treatment, compared to the
immediate treatment, differentially affected the microglia/
macrophages and their distribution at the lesion site. We
found that the inhibition of CSPG synthesis during the
subacute phase (delayed [day 2] treatment), resulted in
increased IGF-1 immunolabeling (Figure 5A) and increased
protein secretion (determined by ELISA; Figure 5B) relative
to the PBS control. Treatment on day 7 had no effect on IGF-
1 levels. TNF-a levels, in contrast to those with the immediate
inhibition of CSPG synthesis, were not affected by the
delayed (day 2) treatment, while the immediate inhibition
of CSPG synthesis resulted in increased TNF-a levels (11 6
1.29 pg/ml in the PBS-treated group versus 16.9 6 3.1 pg/ml
in the xyloside treatment group; Student t-test, p ¼0.004; n ¼
4 mice per group; determined by ELISA).
As described above, CSPG participated in the spatial
organization of the microglia/macrophages at the lesion site;
in the absence of CSPG (in mice receiving xyloside treatment
immediately after the injury), the compartmentalized organ-
ization of the site was disrupted and macrophages also
invaded the epicenter of the lesion (Figure 2I). We therefore
analyzed the distribution of the blood-borne monocytes
following delayed (day 2) treatment with xyloside, conditions
that resulted in improved recovery. We found that when
CSPG production was limited to the acute phase by the
delayed administration of xyloside, the spatial organization of
the microglia/macrophages at the lesion site was maintained
(Figure 5C and 5D).
CSPG Activates Microglia to Acquire a Noncytotoxic,
Beneficial Phenotype
To gain insight into the underlying mechanism of CSPG
effects on microglia/macrophages, we employed in vitro
assays using primary cultures of mouse microglia. Microglia
cultured on an inert substrate, PDL, were used as a basal
reference. Cultured microglia at rest do not show the classical
ramiﬁed morphology of microglia in vivo [46]. Nevertheless,
we observed morphological changes in the microglia cultured
on CSPG relative to those cultured on PDL (Figure 6A). The
morphology of microglia cultured on CSPG had a ‘‘fried egg’’
morphology, with ﬂattened and thickened membrane pro-
cesses and a larger cell body (mean 6 SD 37 6 10 lmi n
CSPG-cultured microglia versus 21 6 5.6 lm on a PDL base;
Student t-test, p , 0.0001), a morphology associated with
microglial activation [47]. Increased incorporation of the cell-
proliferation marker BrdU demonstrated signiﬁcantly in-
creased proliferation of the microglia cultured on CSPG
relative to those cultured on PDL (Figure 6B and 6C).
Examination of the direct effect of CSPG on microglial
expression of BDNF and IGF-1 in vitro, in line with our
results in vivo, revealed an increase in the mRNA of IGF-1 but
not of BDNF (Figure 6D). Analysis of the cells at the protein
level revealed an increase in IGF-1 expression in microglia
cultured on CSPG relative to those cultured on PDL (Figure
6E and 6F). However, no effect on the expression BDNF was
observed (Figure 6E).
IGF-1 is recognized as a key factor in neuronal survival [48]
and can act in either an autocrine or a paracrine manner
[49,50]. Comparison of gene arrays of microglia cultured on
CSPG versus those grown on PDL (Tables S1–S3) revealed
that a group of IGF-1–related genes was increased after
incubation of microglia on CSPG but not on PDL. In order to
determine whether IGF-1 affects CSPG-activated microglia,
and if the effect is autocrine in nature (as our gene array
analysis suggested), we assayed the mRNA of IRS-1. Expres-
sion of IRS-1 is reportedly increased when microglia are
activated by IGF-1 [51]. PCR analysis indeed revealed an
increase in IRS-1 transcripts in the CSPG-activated microglia
(Figure 6G).
MMPs are endogenous proteolytic enzymes that can
degrade CSPG [52] and are reportedly expressed by activated
microglia/macrophages [53,54]. Because of the relevance of
these enzymes as potential players in the feedback regulation
of CSPG levels in injured tissue, we examined the expression
of MMP-2 and MMP-9, two of the most prominent MMPs in
the injured CNS. mRNA levels of MMP-2 and MMP-9 were
analyzed at different time points in microglia cultured on
CSPG and compared to microglia cultured on PDL. Both
MMP-2 and MMP-9 were more abundant in the CSPG-
activated microglia than in the microglia cultured on PDL
(Figure 6H). Compared to MMP-2, MMP-9 levels were
increased at an earlier time point. Our data thus suggest
that CSPG can directly activate microglia to express IGF-1
and MMPs.
Examination of the microglia cultured on CSPG revealed
no detectable increase in nitric oxide (measured in terms of
nitrate levels in the cultured media; Figure 6I) or in TNF-a
mRNA (Figure 6J) relative to microglia cultured on PDL. In
agreement with other studies, activation of microglia by LPS
resulted in their expression of a cytotoxic phenotype [55] in
which nitric oxide and TNF-a were markedly increased
(Figure 6I and 6J). However, when we incubated microglia on
CSPG before exposing them to LPS, their TNF-a production,
determined by immunocytochemistry, was signiﬁcantly lower
than that produced by LPS-activated microglia that were not
pre-exposed to CSPG (Figure 6K and 6M). In addition, the
microglia cultured on CSPG, when subsequently exposed to
LPS, differed from LPS-activated microglia with respect to
the increase in cell-body size (Figure 6L and 6M). Taken
together, our ﬁndings suggest that CSPG can balance out the
production of potentially cytotoxic compounds and concom-
itantly induce expression of speciﬁc neurotrophic factors.
Interaction of Microglia with CSPG Is Mediated by the
CD44 Receptor
CD44 is a well-characterized receptor of CSPG [55]. To
determine whether the interaction of microglia with CSPG
occurs, at least in part, via the CD44 receptor, we examined
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effector molecules. Activation by CD44 is known to induce
phosphorylation of ERK1/2 [56]. Having ﬁrst established
immunocytochemically that ERK1/2 phosphorylation occurs
in CSPG-activated microglia (Figure 7), we showed that such
phosphorylation was signiﬁcantly decreased by the addition
of anti-CD44 neutralizing antibodies (Figure 7). CD44
activation has also been shown to induce expression of IGF-
1 [57].
Products of CSPG Degradation Promote Recovery from
Spinal Cord Injury
Some of the most important lines of evidence supporting a
negative effect of CSPG on CNS repair come from studies in
which degradation of CSPG by ChABC, even if it is
administered immediately after an insult [1,12], results in
improved recovery. Those results appear to contradict our
present ﬁndings that when CSPG biosynthesis is prevented
immediately after a spinal cord injury, recovery is worse than
spontaneous recovery. This apparent discrepancy might be
explained, at least in part, by the fact that degradation of
molecules, unlike inhibition of biosynthesis, leads to the
formation of new compounds that are themselves often
functional [58]. Increasing evidence indicates that many
degradation products of biological compounds themselves
possess potent biological activity [58,59]. With respect to the
proteoglycans, for example, sugar compounds derived from
heparan sulfate proteoglycan were shown to participate in
wound repair and termination of inﬂammatory responses
[58,59].
In the case of CSPG, its degradation by ChABC results in
the formation of a 6-sulfated disaccharide (CSPG-DS) [60],
which exhibits potent neuroprotective properties in several
models of neurotoxicity and neuronal degeneration [60].
Accordingly, we postulated that at least part of the reported
beneﬁcial effect of CSPG degradation might be attributable
to this neuroprotective compound (and possibly also to
others) formed as a result of its speciﬁc enzymatic degrada-
tion with ChABC. To examine the potential beneﬁcial role of
CSPG degradation products, we repeatedly injected CSPG-DS
intravenously after spinal cord injury in mice. The choice of
the dosage and the regimen (days 1, 4, 7, 10, and 13) was based
on our previous study [60]. The mean BMS scores used to
follow the functional recovery of groups of spinally injured
mice treated with CSPG-DS or PBS are shown for each day
tested (Figure 8A). Scores achieved by individual mice on day
60 are shown in Figure 8B. Mice treated with CSPG-DS
recovered signiﬁcantly better than PBS-treated controls,
resulting in a degree of hind-limb coordination that was
not observed in the PBS-treated group.
Immunohistochemical analysis of the lesion site using anti-
CSPG antibody revealed that treatment with CSPG-DS had
no effect on CSPG levels, indicating that the beneﬁcial effect
of CSPG-DS treatment was not caused indirectly by inhib-
ition of CSPG expression (Figure 8C).
Staining for GFAP and IB-4 indicated signiﬁcant tissue
preservation in the CSPG-DS–treated mice relative to
controls treated with PBS (Figure 8D and 8E), so to verify
tissue preservation we analyzed the spinal cords of CSPG-DS
treated or PBS-treated mice for the presence of descending
ﬁbers below the lesion site, using stereotactic anterograde
tracing of BDA administered to the motor cortexes (Figure
8F).
We also examined the potential effects of CSPG-DS on
microglia in vitro. Incubation of microglia on PDL in the
presence of CSPG-DS resulted, as with the intact CSPG, in a
dose-dependent increase in IGF-1 levels (Figure 8G and 8H).
In contrast to the ﬁnding with intact CSPG, we also observed
an increase in BDNF levels (Figure 8I and 8J). These results
showed that intact CSPG and CSPG-DS do not have
completely overlapping effects, indicating that they operate
via different mechanisms of action. We also examined
whether CSPG-DS can balance out the inhibitory effect of
LPS on IGF-1 production. By preincubating microglia with
CSPG-DS it was possible to overcome the LPS-induced
inhibition of IGF-1 expression in vitro (Figure 8G and 8H).
To further study the effect of CSPG-DS in vivo, we
examined the injured spinal cords treated with CSPG-DS or
PBS for IGF-1 and BDNF (Figure 8K and 8L). Treatment with
CSPG-DS signiﬁcantly increased BDNF and IGF-1 in the
injured site. The increase in IGF-1-expressing microglia was
not restricted to the cells associated with the margins of the
lesion (Figure 8L).
Discussion
The results of this study suggest that CSPG, an extracellular
component of the glial scar, exerts a beneﬁcial effect on CNS
recovery from injury, in part by inducing IGF-1 and MMP
expression by microglia/macrophages and attenuating TNF-a
levels. This microglial modulation was mediated, at least in
part, by the CD44 receptor. Our data further suggest that,
following injury to the CNS, CSPG plays a beneﬁcial role in its
recovery that can be achieved only by careful regulation of its
presence: blockage of CSPG production immediately after
spinal cord injury decreased spontaneous recovery, whereas
restriction of CSPG biosynthesis to the acute phase improved
recovery.
The intensive secretion of CSPG reported after a CNS
injury [1,10,42] has been largely blamed for the lack of axonal
regeneration and the detrimental outcome following injuries
to the spinal cord. Moreover, the increase in CSPG observed
in various CNS pathologies (such as multiple sclerosis and
Alzheimer disease) [61,62] led to the widespread perception
that the postinjury production of CSPG is a manifestation of
CNS malfunction. Accordingly, treatments were developed to
overcome the growth-inhibitory effect of this molecule,
mainly by inducing its degradation by the speciﬁc enzyme
ChABC [12]. The results of the present study, however,
highlight a novel aspect of this molecule in regulating the
local immune response via modulation of microglia/macro-
phage expression of IGF-1 and suggest that the postinjury
production of CSPG in the acute phase plays an important
role in the repair process.
The contribution of blood-borne monocytes to the
recovery is still a subject of debate [5,21,32,63–65]. Using
chimeric mice with GFP-expressing blood-borne monocytes,
we demonstrated that both microglia and macrophages that
were found in CSPG-rich areas expressed IGF-1, a phenom-
enon that was abolished when CSPG production was
inhibited. Thus the present study suggests that CSPG
modulates the behavior of microglia/macrophages and there-
by affects their contribution to the overall repair process.
PLoS Medicine | www.plosmedicine.org August 2008 | Volume 5 | Issue 8 | e171 1274
Chondroitin in Spinal Cord RepairNevertheless, in vivo, it is likely that additional factors besides
CSPG contribute to the behavior of resident and recruited
cells. Moreover, CSPG itself might have additional differential
effects on the activation of microglia or macrophages and
regulate other aspects of microglial cell/macrophage pheno-
type (such as phagocytosis or neurotrophic factor secretion).
The direct role of CSPG in controlling microglial and
macrophage behavior after spinal cord injury was demon-
strated here by blockage of CSPG biosynthesis, rather than
inducing its degradation of existing CSPG. Degradation,
unlike blockage of biosynthesis, can result in the formation of
potentially new CSPG-derived active compounds such as
CSPG-DS. Blockage of biosynthesis immediately after the
injury resulted in reduced expression of IGF-1 by microglia/
macrophages, loss of cellular compartmentalization in the
lesion site, and decreased functional recovery relative to
untreated controls. In contrast, when CSPG biosynthesis was
allowed to take place during the ﬁrst 2 d and was then
inhibited, this treatment resulted in enhanced recovery,
preservation of the site organization and of neurotrophic
factor levels. Moreover, since both treatments (immediate
and delayed to day 2) resulted in overall decrease in CSPG
levels, it is likely that the improved recovery observed in the
delayed treatment (day 2) should be attributed mostly to the
presence of CSPG in the acute phase after injury.
Thus, these results indicate that the effect of CSPG after
spinal cord injury is not an all-or-none phenomenon; it is a
function of timing and level. Accordingly, our observations
might explain some of the results described in the literature,
in which various conditions of enzymatic degradation led to
differing extents of recovery. For example, moderate (rather
than intense) application of CSPG-degrading enzymes was
reportedly more effective than intensive degradation [66].
Other lines of evidence indicate that astrocytes (the main
source of CSPG) are required in CNS repair [67,68],
speciﬁcally in the acute phase after injury, but not in the
chronic phase [67]. In agreement with our study, pharmaco-
logical blockage of the MMPs, a family of endogenous
proteolytic enzymes that degrade CSPG in the glial scar
[52], when limited to the ﬁrst 3 d after spinal cord injury,
improves locomotor activity [69]. Our study further suggests
that in those studies in which a beneﬁcial effect of CSPG
degradation by ChABC was documented it was, at least in
part, an outcome of the production of new molecules, for
example disaccharides (CSPG-DS), rather than simply the
elimination of CSPG. Accordingly, in the present study
CSPG-DS did directly modulate the microglial phenotype
both in vitro and in vivo, without affecting the levels of CSPG.
Although we demonstrated that the intact CSPG and its
disaccharidic derivatives can independently affect microglia
and promote recovery, we did not rule out the possibility that
glycosaminoglycans, the saccharidic component of the
proteoglycan, are the relevant active components responsible
for the beneﬁcial activity of the intact CSPG.
The observation that CSPG induces MMP expression by
microglia in vitro, in light of the need for temporally
regulated degradation of CSPG in the process of repair,
might point to a potential feedback regulation of CSPG by
the same microglia/macrophages as those activated by it. This
point, however, requires further investigation.
To conclude, our study does not argue against the beneﬁcial
effect of CSPG degradation, but rather suggests that the
timing and the extent of degradation should be carefully
selected according to the changing requirements of the
ongoing dynamic repair process [70]. In its intact form, CSPG
is required at the early stages of recovery to activate microglia/
macrophages and possibly to limit the spread of damage by
creating a physical barrier, whereas in the chronic postinjury
phase, or when present in excessive amounts, CSPG inhibits
axonal growth and regeneration. Regulation of CSPG ex-
pression may have a role in the repair of minor injuries but is
inadequate for major CNS traumas. Moreover, since CSPG is a
major constituent of the glial scar, the present ﬁndings raises
the potential need to revisit the overall perception of the glial
scar and its role in recovery. A better understanding of the
regulation of the scar tissue and the role of the naturally
occurring CSPG in health and disease will enable us to
increase the beneﬁt of endogenous repair mechanisms and
improve many of the available therapies for CNS injury.
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Editors’ Summary
Background. Every year, spinal cord injuries paralyze about 10,000
people in the United States. The spinal cord, which contains bundles of
nervous system cells called neurons, is the communication superhighway
between the brain and the body. Messages from the brain travel down
the spinal cord to control movement, breathing, and other bodily
functions; messages from the skin and other sensory organs travel up the
spinal cord to keep the brain informed about the body. All these
messages are transmitted along axons, long extensions on the neurons.
The spinal cord is protected by the bones of the spine but if these are
displaced or broken, the axons can be compressed or cut, which
interrupts the information flow. Damage near the top of the spinal cord
paralyzes the arms and legs (tetraplegia); damage lower down paralyzes
the legs only (paraplegia). Spinal cord injuries also cause other medical
problems, including the loss of bowel and bladder control. Currently
there is no effective treatment for spinal cord injuries. Treatment with
drugs to reduce inflammation has, at best, only modest effects.
Moreover, because damaged axons rarely regrow, most spinal cord
injuries are permanent.
Why Was This Study Done? One barrier to recovery after a spinal cord
injury seems to be an inappropriate immune response to the injury. After
an injury, microglia (immune system cells that live in the nervous
system), and macrophages (blood-borne immune system cells that
infiltrate the injury) become activated. Microglia/macrophage activation
can be either beneficial (the cells make IGF-1, a protein that stimulates
axon growth) or destructive (the cells make TNF-a, a protein that kills
neurons), so studies of microglia/macrophage activation might suggest
ways to treat spinal cord injuries. Another possible barrier to recovery is
‘‘chondroitin sulfate proteoglycan’’ (CSPG). This is a major component of
the scar tissue (the ‘‘glial scar’’) that forms around spinal cord injuries.
CSPG limits axon regrowth, so attempts have been made to improve
spinal cord repair by removing CSPG. But if CSPG prevents spinal cord
repair, why is so much of it made immediately after an injury? In this
study, the researchers investigate this paradox by asking whether CSPG
made in the right place and in the right amount might have a beneficial
role in spinal cord repair that has been overlooked.
What Did the Researchers Do and Find? The researchers bruised a
small section of the spinal cord of mice to cause hind limb paralysis, and
then monitored the recovery of movement in these animals. They also
examined the injured tissue microscopically, looked for microglia and
infiltrating macrophages at the injury site, and measured the production
of IGF-1 and TNF-a by these cells. Inhibition of CSPG synthesis
immediately after injury impaired the functional recovery of the mice
and increased tissue loss at the injury site. It also altered the spatial
organization of infiltrating macrophages at the injury site, reduced IGF-1
production by these microglia/macrophages, and increased TNF-a levels.
In contrast, when CSPG synthesis was not inhibited until two days after
the injury, the mice recovered well from spinal cord injury. Furthermore,
the interaction of CSPG with a cell-surface protein called CD44 activated
microglia/macrophages growing in dishes and increased their produc-
tion of IGF-1 but not of molecules that kill neurons.
What Do These Findings Mean? These findings suggest that,
immediately after a spinal cord injury, CSPG is needed for the repair of
injured neurons and the recovery of movement, but that later on the
presence of CSPG hinders repair. The findings also indicate that CSPG has
these effects, at least in part, because it regulates the activity and
localization of microglia and macrophages at the injury site and thus
modulates local immune responses to the damage. Results obtained
from experiments done in animals do not always accurately reflect the
situation in people, so these findings need to be confirmed in patients
with spinal cord injuries. However, they suggest that the effect of CSPG
on spinal cord repair is not an inappropriate response to the injury, as is
widely believed. Consequently, careful manipulation of CSPG levels
might improve outcomes for people with spinal cord injuries.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050171.
  The MedlinePlus encyclopedia provides information about spinal cord
injuries; MedlinePlus provides an interactive tutorial and a list of links
to additional information about spinal cord injuries (in English and
Spanish)
  The US National Institute of Neurological Disorders and Stroke also
provides information about spinal cord injury (in English and Spanish)
  Wikipedia has a page on glial scars (note: Wikipedia is a free online
encyclopedia that anyone can edit; available in several languages)
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